Latest Content

Approval of Biogen's high-dose Spinraza strengthens the company’s lifecycle strategy in SMA, enhancing durability while reinforcing competitive positioning in a rapidly evolving neurology market.

In today's Pharmaceutical Executive Daily, Eli Lilly presses the U.K. government to overhaul its NHS drug pricing framework as a condition of resuming investment in the country, Lilly also announces a deal worth up to $2.75 billion with AI drug discovery company Insilico Medicine to accelerate development of novel therapeutics across multiple disease areas, and Pharmaceutical Executive speaks with the co-founder and CEO of Soley Therapeutics about the company's biology-first approach to drug discovery.

Eli Lilly warns that the UK's current framework is undermining investment and could impact future launches and manufacturing decisions.

The agreement grants Lilly an exclusive worldwide license to a portfolio of preclinical oral therapeutics.

As opposed to starting with a target disease, Yerem Yeghiazarians, MD discusses how Soley instead focused on developing a method of identifying broad compounds.

In today's Pharmaceutical Executive Daily, Novartis agrees to acquire Excellergy for up to $2 billion to advance a next-generation anti-IgE therapy while Otsuka moves to acquire Transcend Therapeutics in a deal valued at up to $1.225 billion, the FDA approves two first-of-their-kind therapies in Novo Nordisk's once-weekly basal insulin Awiqli and Rocket Pharmaceuticals' gene therapy Kresladi for a rare pediatric immune disease, and a new commentary argues that orphan drug manufacturers should be proactively evaluating risk contracting as a hedge against an emerging downward pricing environment.

While they may be linked, the administration’s DTC drug coupon site is not necessarily the entirety of its MFN efforts.

Kresladi becomes the first FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2, and Awiqli the first and only once-weekly basal insulin treatment for adults with type 2 diabetes.

Novartis and Otsuka Pharmaceutical are advancing deals to expand pipelines in allergy and psychiatry, with Novartis targeting next-generation anti-IgE therapy and Otsuka betting on a rapid-acting PTSD treatment.

In today's Pharmaceutical Executive Daily, the Trump administration misses a statutory deadline to nominate a permanent CDC director, leaving the agency in continued leadership limbo, the FDA grants accelerated approval to Denali Therapeutics' Avlayah as the first therapy designed to cross the blood-brain barrier and treat the neurological manifestations of Hunter syndrome, and a new commentary breaks down what CMS's updated ASP reporting requirements mean for Part B drug manufacturers ahead of a key April deadline.

The White House postponed naming a permanent CDC director as the Trump administration navigates competing political pressures ahead of midterm elections.

FDA has granted accelerated approval to Avlayah, the first therapy engineered to cross the blood-brain barrier and treat the neurological manifestations of Hunter syndrome.

For pharma products, ensuring proper delivery requires the majority of work to occur before the product hits the road.